Systems medicine in acute myeloid leukemia (AML) and beyond

Tue2  Sep09:15am(45 mins)
Charter 3
Keynote Speaker:


We have set up an individualized systems medicine (ISM) programme to facilitate implementation of precision medicine. A proof of concept study was recently published in AML (Pemovska et al., Cancer Discov. 2013 Dec;3(12):1416-29). We are now expanding the programme to include other hematological cancers and progenitor cell cultures from solid tumors. The ISM strategy as implemented in AML is composed of DNA/RNA sequencing as well as phosphoproteomic profiling of patient cells, determination of ex-vivo cancer drug sensitivity testing to >300 drugs, and translation of key findings to the clinic in the form of individualized therapy suggestions. This systems medicine programme provides an opportunity for continuous “real-time” adjustment of cancer therapies for individual patients.

Hosted By

The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Eventflo Home
copyright ELRIG,, Labhoo Ltd 2003-2021